SCHEMBL6278533

SCHEMBL6278533

C/C(=N/NC(=N)N)c1cn(S(=O)(=O)c2ccc(-c3ccccc3)cc2)c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
PLK1 P53350 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
AKR1C3 P42330 1/20 0.48
AKR1C1 Q04828 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
ALOX5 P09917 4/20 0.45
PTGS2 P35354 1/20 0.45
HTR6 P50406 6/20 0.44
TNF P01375 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
TNFSF11 O14788 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6278536 1.00 LMNA (0.53) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6286909 0.94 LMNA (0.60) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6286906 0.94 LMNA (0.60) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6284670 0.91 LMNA (0.51) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6285310 0.91 HTR6 (0.54) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6284673 0.91 LMNA (0.51) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6285302 0.91 HTR6 (0.54) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6278581 0.90 LMNA (0.50) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6283829 0.90 AKR1C3 (0.60) LMNASMN1; SMN2PLK1MEN1KMT2A
SCHEMBL6283832 0.90 AKR1C3 (0.60) LMNASMN1; SMN2PLK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A LMNA 4212/4885SMN1; SMN2 3120/4885PLK1 2857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.